目的：分析益赛普联合沙利度胺用于治疗难治性强直性脊柱炎的临床治疗效果。方法：对2010年6月-2012年11月期间本院收治的55例难治性强直性脊柱炎患者的临床数据进行系统分析，随机将55例患者分成对照组和治疗组，对照组采用柳氮磺胺嘧啶（SASP）治疗，治疗组采取益赛普联合沙利度胺治疗，观察两组患者的C反应蛋白、外周关节肿胀数、疼痛数、扩胸度、枕壁试验、关节功能指数以及红细胞沉降率等指标的情况。结果：治疗组患者的各项指标情况在治疗后均高于对照组，临床缓解的时间为（40.1±2.2）d，优于对照组的（68.5±5.2）d，差异均具有统计学意义（P<0.05）。结论：临床中使用益赛普联合沙利度胺治疗难治性强直性脊柱炎，能够有效缓解病症，有效控制复发，治疗效果显著，值得推广应用。%Objective:To analysis the clinical treatment effect of the Etanercept with Thalidomide used to intractable ankylosing spondylitis, providing reference data for the clinical diagnosis and treatment. Method:In June 2010 to November 2012 the clinical data of 55 cases of intractable ankylosing spondylitis patients were statistically analysed,all patients were divided into two groups:control group and experimental group.The comparison group used the willow nitrogen sulfadiazine(SASP)treatment,the experimental group took the general joint Sally degree amine treatment,The two groups were observed the c-reactive protein,peripheral joint swelling number,number of pain,chest expansion degree,pillow wall test,joint function index and erythrocyte sedimentation rate and the index. Result:The results of the comparison,compared to the willow nitrogen sulfadiazine therapy,the patients in the clinical significant efficiency and clinical relief,other each target situation after treatment were higher than those in the control group,Clinical ease time was(40.1±2.2)days,due to the control group(68.5±5.2)days,compared with control group treatments with significant difference(P<0.05). Conclusion:The clinical use of the Etanercept with Thalidomide used to intractable ankylosing spondylitis,can effectively relieve disease,effective control of recurrence,the treatment effect is remarkable,and it is worth for spreading application.
展开▼
